Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicholas P Restifo

Showing results (11-20 of 260) with videos related to

Pageof 26
Sort By:
Current Opinion in Immunology|March 17, 2009
Adoptive immunotherapy of cancer using CD4(+) T cellsPawel Muranski, Nicholas P Restifo
Current Opinion in Immunology|October 24, 2013
Lineage relationship of effector and memory T cellsNicholas P Restifo, Luca Gattinoni
Current Opinion in Immunology|March 16, 2005
Less is more: lymphodepletion followed by hematopoietic stem cell transplant augments adoptive T-cell-based anti-tumor immunotherapyClaudia Wrzesinski, Nicholas P Restifo
Nature Medicine|August 8, 2012
Nine lives for TH9s?Weiping Zou, Nicholas P Restifo
Journal of Immunotherapy (Hagerstown, Md. : 1997)|February 24, 2005
CD4+CD25+ T regulatory cells, immunotherapy of cancer, and interleukin-2Paul Andrew Antony, Nicholas P Restifo
The Lancet. Oncology|January 5, 2005
Use of standard criteria for assessment of cancer vaccinesNicholas P Restifo, Steven A Rosenberg
Cell|October 8, 2016
Customizing Functionality and Payload Delivery for Receptor-Engineered T CellsChristopher A Klebanoff, Nicholas P Restifo
Nature|December 18, 2019
Identifying the source of tumour-infiltrating T cellsSuman Kumar Vodnala, Nicholas P Restifo
Journal of Immunotherapy (Hagerstown, Md. : 1997)|May 10, 2002
Do CD4+ CD25+ immunoregulatory T cells hinder tumor immunotherapy?Paul Andrew Antony, Nicholas P Restifo
Cancer Research|June 23, 2012
Cellular constituents of immune escape within the tumor microenvironmentSid P Kerkar, Nicholas P Restifo
Pageof 26

Showing results (11-20 of 260) with videos related to

Sort By:
Pageof 26
Current Opinion in Immunology|March 17, 2009
Adoptive immunotherapy of cancer using CD4(+) T cellsPawel Muranski, Nicholas P Restifo
Current Opinion in Immunology|October 24, 2013
Lineage relationship of effector and memory T cellsNicholas P Restifo, Luca Gattinoni
Current Opinion in Immunology|March 16, 2005
Less is more: lymphodepletion followed by hematopoietic stem cell transplant augments adoptive T-cell-based anti-tumor immunotherapyClaudia Wrzesinski, Nicholas P Restifo
Nature Medicine|August 8, 2012
Nine lives for TH9s?Weiping Zou, Nicholas P Restifo
Journal of Immunotherapy (Hagerstown, Md. : 1997)|February 24, 2005
CD4+CD25+ T regulatory cells, immunotherapy of cancer, and interleukin-2Paul Andrew Antony, Nicholas P Restifo
The Lancet. Oncology|January 5, 2005
Use of standard criteria for assessment of cancer vaccinesNicholas P Restifo, Steven A Rosenberg
Cell|October 8, 2016
Customizing Functionality and Payload Delivery for Receptor-Engineered T CellsChristopher A Klebanoff, Nicholas P Restifo
Nature|December 18, 2019
Identifying the source of tumour-infiltrating T cellsSuman Kumar Vodnala, Nicholas P Restifo
Journal of Immunotherapy (Hagerstown, Md. : 1997)|May 10, 2002
Do CD4+ CD25+ immunoregulatory T cells hinder tumor immunotherapy?Paul Andrew Antony, Nicholas P Restifo
Cancer Research|June 23, 2012
Cellular constituents of immune escape within the tumor microenvironmentSid P Kerkar, Nicholas P Restifo
Pageof 26